50 results
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
28 Jun 24
Departure of Directors or Certain Officers
5:00pm
into as of June 26, 2024 (the “Effective Date”), by and between MIRA Pharmaceuticals, Inc. (the “Company”) and Michelle Yanez (“Employee”).
WHEREAS … , the Company and the Employee entered into that certain Employment Agreement dated as of April 28, 2023 (the “Previous Employment Agreement”); and
WHEREAS
10-K
2023 FY
EX-4.4
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
future public offerings to raise additional capital, acquisitions of other businesses or entities and issuances under employee benefit plans … at the corporation’s request as a director or officer, manager, partner, trustee, employee, or agent of another domestic or foreign corporation
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
noncompliance with regulatory standards and requirements.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could … or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information, including information obtained during
8-K
MIRA
Mira Pharmaceuticals Inc
13 Mar 24
Departure of Directors or Certain Officers
4:30pm
resignation both as Executive Chairman and as an employee of the Company, effective immediately, citing his desire to focus his time on his role as Chairman
8-K
EX-10.1
7o7x5zapl531 r7
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
10-Q
yo5vmh 6qk4ryo97i
15 Sep 23
Quarterly report
4:45pm
8-K
EX-10.1
ts5513k9e
31 Aug 23
Departure of Directors or Certain Officers
5:27pm
8-K
EX-10.2
dc3k71
31 Aug 23
Departure of Directors or Certain Officers
5:27pm
8-K
EX-1.1
4ecl 49v2st
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
zvks25oyiqm3ohc46z
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
1kmehquce
4 Aug 23
Prospectus with pricing info
12:59pm